Advice
following a full submission:
caspofungin acetate (Caspofungin) is accepted for restricted use within NHS Scotland.
Caspofungin provides an additional agent for the treatment of invasive candidiasis. Its use should be restricted to patients with fluconazole-resistant Candida infection who do not respond to, or cannot tolerate amphotericin B therapy or who are at an increased risk of serious side effects with amphotericin (eg. transplant patients, especially those receiving bone marrow transplants).
Download detailed advice19KB (PDF)
Medicine details
- Medicine name:
- caspofungin acetate (Caspofungin)
- SMC ID:
- 74/03
- Indication:
- Invasive candidiasis
- Pharmaceutical company
- MSD
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 January 2004